Ghaidaa Elmehallawy
Research Subjects
Ghaidaa Elmehallawy has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Ali Amer M. Alghamdi
1 shared publicationHamza M. Alayoubi
1 shared publication- Hassan Ali A AlZubaidi
Department of Family Medicine, King Abdulaziz Medical City, Jeddah 22384, Saudi Arabia
1 shared publication - Lama M. Albelowi
Dermatology Department, King Salman bin Abdulaziz Medical City, Medina, Saudi Arabia
1 shared publication Randa E. Dafaalla
1 shared publication
Latest Publications
- Open Access
- 1 June 2026
- Published by Saudi Medical Horizons Journal in Saudi Medical Horizons Journal
- Vol. 6 (2) , 275-282
The Role of JAK Inhibitors in Atopic Dermatitis, Alopecia Areata, and Vitiligo: A Review article
Janus kinase (JAK) inhibitors have emerged as a groundbreaking option in dermatologic therapy, offering a more precise approach to manage inflammatory and autoimmune skin diseases. This narrative review explores the use of JAK inhibitors in three key conditions: atopic dermatitis, alopecia areata, and vitiligo. These disorders share a common underlying mechanism involving disruption of the JAK-STAT signaling pathway, which contributes to abnormal immune responses. A growing body of clinical research highlights the effectiveness of both topical and oral JAK inhibitors in managing symptoms across these conditions. For instance, ruxolitinib cream and oral agents such as abrocitinib, baricitinib, and upadacitinib have shown strong anti-inflammatory effects and relief of itching in atopic dermatitis. In the treatment of alopecia areata, medications like baricitinib, ritlecitinib, and the recently approved deuruxolitinib have brought renewed optimism for individuals with more severe forms of the disease. Meanwhile, topical ruxolitinib has shown promise in restoring pigment, particularly on facial areas affected by vitiligo. Although these therapies are generally well-tolerated, potential risks such as infections and cardiovascular concerns necessitate ongoing safety monitoring. Overall, this review brings together the latest evidence on the use of JAK inhibitors in dermatology, highlighting their clinical impact and underscoring the need for continued research to optimize long-term safety and patient selection.
- 1 June 2026
- Published by Saudi Medical Horizons Journal in Saudi Medical Horizons Journal
- Vol. 6 (2) , 275-282
Open AccessThe Role of JAK Inhibitors in Atopic Dermatitis, Alopecia Areata, and Vitiligo: A Review article
Janus kinase (JAK) inhibitors have emerged as a groundbreaking option in dermatologic therapy, offering a more precise approach to manage inflammatory and autoimmune skin diseases. This narrative review explores the use of JAK inhibitors in three key conditions: atopic dermatitis, alopecia areata, and vitiligo. These disorders share a common underlying mechanism involving disruption of the JAK-STAT signaling pathway, which contributes to abnormal immune responses. A growing body of clinical research highlights the effectiveness of both topical and oral JAK inhibitors in managing symptoms across these conditions. For instance, ruxolitinib cream and oral agents such as abrocitinib, baricitinib, and upadacitinib have shown strong anti-inflammatory effects and relief of itching in atopic dermatitis. In the treatment of alopecia areata, medications like baricitinib, ritlecitinib, and the recently approved deuruxolitinib have brought renewed optimism for individuals with more severe forms of the disease. Meanwhile, topical ruxolitinib has shown promise in restoring pigment, particularly on facial areas affected by vitiligo. Although these therapies are generally well-tolerated, potential risks such as infections and cardiovascular concerns necessitate ongoing safety monitoring. Overall, this review brings together the latest evidence on the use of JAK inhibitors in dermatology, highlighting their clinical impact and underscoring the need for continued research to optimize long-term safety and patient selection.